Across TCGA pan-cancer cohorts, KRTAP17-1 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated KRTAP17-1 data layer compared with 4 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher KRTAP17-1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP17-1 expression acts as an unfavorable survival marker, although some lineages such as SCLC and OV show a favorable association.
LUAD, SCLC, and SKCM are the cancer types where KRTAP17-1 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.